However, although it displays activity against CML progenitors, the prospects for ABT-263 as a therapeutic agent are hampered by its inhibitory effect on BCL-XL, which is critical for platelet survival (102–104). This evidence concerns the gene BCL2L1 and chronic myelogenous leukemia, BCR-ABL1 positive.